<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475734</url>
  </required_header>
  <id_info>
    <org_study_id>108372</org_study_id>
    <nct_id>NCT01475734</nct_id>
  </id_info>
  <brief_title>Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Single-site, Randomized, Double-blind, Placebo-controlled, Parallel-group, Stepped Glucose Clamp Study to Assess the Effects of Albiglutide on Counter-regulatory Hormone Responses and Recovery From Hypoglycemia in Subjects With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a stepped glucose clamp study designed to investigate the effect of treatment with
      albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in
      subjects with Type 2 diabetes mellitus. A single dose of albiglutide or placebo will be given
      prior to a stepped hyper- and hypoglycemic clamp. The goal of this study is to demonstrate
      that albiglutide increases insulin secretion and decreases glucagon levels in a
      glucose-dependent manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, single-site, randomized, double-blind, parallel-group,
      placebo-controlled, stepped glucose clamp study designed to investigate the effect of
      treatment with albiglutide on counter-regulatory hormone responses and recovery from
      hypoglycemia in subjects with Type 2 diabetes mellitus. A single dose of albiglutide or
      placebo will be given 3 days before employing a stepped hyper- and hypoglycemic clamp. The
      goal of this study is to demonstrate that albiglutide increases insulin secretion and
      decreases glucagon levels in a glucose-dependent manner. In particular, this study is being
      conducted to ensure that albiglutide does not impair counter-regulatory responses during
      hypoglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure</measure>
    <time_frame>Day 4</time_frame>
    <description>Plasma glucagon levels were measured for the estimation of glucagon secretion during the hypoglycemic periods. Glucagon response was measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on non-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification (0.03780 nmol/L) were set to the quantification limit for summary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Secretion Rate (Measured by Mathematical Analysis of C-peptide Concentrations) During the Glucose Clamp Period</measure>
    <time_frame>Day 4</time_frame>
    <description>The insulin secretion rate (ISR) was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters. ISR was measured at 1 hr, 1 hr 15 min, 1 hr 45 min, 2 hr, 2 hr 45 min, 3 hr, 3 hr 30 min, 3 hr 45 min, 4 hr 15 min, and 4 hr 30 min. Repeated-measures analysis of variance was performed on insulin secretion rate using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epinephrine Values During the Glucose Clamp Period</measure>
    <time_frame>Day 4</time_frame>
    <description>Epinephrine levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine Values During the Glucose Clamp Period</measure>
    <time_frame>Day 4</time_frame>
    <description>Norepinephrine levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Hormone Values During the Glucose Clamp Period</measure>
    <time_frame>Day 4</time_frame>
    <description>Growth hormone levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Values During the Glucose Clamp Period</measure>
    <time_frame>Day 4</time_frame>
    <description>Insulin levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol Values During the Glucose Clamp Period</measure>
    <time_frame>Day 4</time_frame>
    <description>Cortisol levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide Values During the Glucose Clamp Period</measure>
    <time_frame>Day 4</time_frame>
    <description>C-peptide levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery Time of Plasma Glucose Levels to &gt;=3.9 mmol/L (&gt;=70 mg/dL) From the Hypoglycemic Clamp Level of 2.8 Nmol/L (50.4 mg/dL)</measure>
    <time_frame>Day 4</time_frame>
    <description>The effect of albiglutide and placebo on the recovery time of plasma glucose levels to &gt;=3.9 mmol/L (7&gt;=0 mg/dL) from the hypoglycemic clamp level of 2.8 nmol/L (50.4 mg/dL) was calculated as the time in minutes between switching off of the insulin infusion and reaching the level of &gt;=3.9 mmol/L (&gt;=70 mg/dL). Censored values were censored at 70 minutes. The median and 95% confidence interval data are obtained from Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Albiglutide Concentration on the Day of the Clamp Procedure</measure>
    <time_frame>Day 4</time_frame>
    <description>Plasma samples were taken from participants at two time points on Day 4 (at 0 hours and 4 hours and 45 minutes post-dose) of Week 1 of the study for albiglutide study drug level analyses. The average concentration for each participant was calculated as the mean of the concentrations at 0 hours and 4 hours 45 minutes. The clamp procedure is a glucose-controlled insulin infusion system. Variable infusions of glucose are administered to achieve various glucose target levels. It is a way of quantifying insulin secretion and resistance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE) and Treatment-emergent Non-serious Adverse Event (AE) During the Clamp Period</measure>
    <time_frame>From the time the participant consented to participate in the study through the end of the study, or the final follow-up visit for participants who discontinued active participation in the study (up to 8 study weeks)</time_frame>
    <description>Treatment-emergent AEs are defined as those with an onset on or after study drug administration. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>albiglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of albiglutide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>albiglutide</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>albiglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Historical diagnosis of type 2 diabetes mellitus for at least 6 months and less than
             10 years before Screening

          -  HbA1c &lt;10% at Screening for subjects who do not require washout of existing OAD or &lt;9%
             at Screening for subjects who do require washout from existing OAD

          -  Body mass index in range 28 kg/m2 to40 kg/m2

        Exclusion Criteria:

          -  History of pancreatitis or current ongoing symptomatic biliary disease or pancreatitis

          -  History of significant gastrointestinal surgery,

          -  History of significant cardiovascular disease

          -  History of a seizure disorder

          -  Documented hypertension or hypotension

          -  Use of oral antidiabetic agents, except for metformin, within 14 days before
             investigational product administration.

          -  Current hepatic disease or abnormal liver function tests

          -  Positive test result for hepatitis B, hepatitis C, or human immunodeficiency virus
             infection 1 or 2

          -  History of regular alcohol consumption (exceeding 7 drinks/week for women or 14
             drinks/week for men)

          -  Female subject is pregnant (confirmed by laboratory testing), lactating, or less than
             6 weeks postpartum

          -  Known allergy to any GLP-1 analog or excipients of albiglutide, Baker's yeast, or
             insulin

          -  History of type 1 diabetes,

          -  Prior exposure to GLP-1 agents, including albiglutide

          -  Blood donation over 500 mL within 8 weeks before Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <results_first_submitted>April 17, 2014</results_first_submitted>
  <results_first_submitted_qc>April 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2014</results_first_posted>
  <disposition_first_submitted>November 21, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 21, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 27, 2012</disposition_first_posted>
  <last_update_submitted>November 20, 2016</last_update_submitted>
  <last_update_submitted_qc>November 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucose clamp</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>rGLP-1 protein</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>108372</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108372</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108372</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108372</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108372</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108372</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>108372</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible participants entered a 1-week Screening Period, a 2-week Run-in/Stabilization Period, a 4-day Treatment Period for the evaluation of efficacy and safety, and an 8-week post-treatment Follow-up Period. A total of 45 participants were screened, 44 were randomized, and 41 completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Albiglutide 50 mg</title>
          <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albiglutide 50 mg</title>
          <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="6.86"/>
                    <measurement group_id="B2" value="48.4" spread="9.32"/>
                    <measurement group_id="B3" value="49.1" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure</title>
        <description>Plasma glucagon levels were measured for the estimation of glucagon secretion during the hypoglycemic periods. Glucagon response was measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on non-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification (0.03780 nmol/L) were set to the quantification limit for summary.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic (PD) Population: all participants who received 1 dose of albiglutide or placebo, had a Baseline assessment, and had at least 1 post-Baseline assessment of the primary endpoint (glucagon) during the clamp procedure. PD Population participants were analyzed according to randomly assigned treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Concentration (Nanomoles Per Liter [Nmol/L]) During the Hypoglycemic Periods of the Glucose Clamp Procedure</title>
          <description>Plasma glucagon levels were measured for the estimation of glucagon secretion during the hypoglycemic periods. Glucagon response was measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on non-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification (0.03780 nmol/L) were set to the quantification limit for summary.</description>
          <population>Pharmacodynamic (PD) Population: all participants who received 1 dose of albiglutide or placebo, had a Baseline assessment, and had at least 1 post-Baseline assessment of the primary endpoint (glucagon) during the clamp procedure. PD Population participants were analyzed according to randomly assigned treatment.</population>
          <units>Nanomoles per liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03780" spread="1.000000"/>
                    <measurement group_id="O2" value="0.03805" spread="1.030606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03780" spread="1.000000"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03783" spread="1.003528"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03780" spread="1.000000"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr, n=20, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03805" spread="1.029775"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03876" spread="1.090802"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03808" spread="1.024552"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04296" spread="1.203416"/>
                    <measurement group_id="O2" value="0.03922" spread="1.127202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04072" spread="1.146327"/>
                    <measurement group_id="O2" value="0.03893" spread="1.086818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03976" spread="1.152056"/>
                    <measurement group_id="O2" value="0.04094" spread="1.192380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03899" spread="1.105904"/>
                    <measurement group_id="O2" value="0.04000" spread="1.146223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03936" spread="1.102107"/>
                    <measurement group_id="O2" value="0.03958" spread="1.116342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03780" spread="1.000000"/>
                    <measurement group_id="O2" value="0.03814" spread="1.042285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03809" spread="1.034545"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03780" spread="1.000000"/>
                    <measurement group_id="O2" value="0.03780" spread="1.000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.791</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.993</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.946</ci_lower_limit>
            <ci_upper_limit>1.043</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 0 hr.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.952</ci_lower_limit>
            <ci_upper_limit>1.050</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 1 hr.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.975</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.953</ci_lower_limit>
            <ci_upper_limit>1.051</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 1 hr 15 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.952</ci_lower_limit>
            <ci_upper_limit>1.050</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 1 hr 45 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.908</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.955</ci_lower_limit>
            <ci_upper_limit>1.053</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 2 hr.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.312</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.977</ci_lower_limit>
            <ci_upper_limit>1.077</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 2 hr 45 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.763</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.960</ci_lower_limit>
            <ci_upper_limit>1.058</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 3 hr.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>1.150</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 3 hr 30 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.046</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.996</ci_lower_limit>
            <ci_upper_limit>1.098</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 3 hr 45 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.238</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.971</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.925</ci_lower_limit>
            <ci_upper_limit>1.020</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 4 hr 15 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.298</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.975</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.928</ci_lower_limit>
            <ci_upper_limit>1.023</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 4 hr 30 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.821</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.994</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.947</ci_lower_limit>
            <ci_upper_limit>1.044</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 4 hr 45 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.715</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>0.991</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.944</ci_lower_limit>
            <ci_upper_limit>1.040</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 5 hr.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.759</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.960</ci_lower_limit>
            <ci_upper_limit>1.058</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 5 hr 15 min.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>ANOVA</method>
            <param_type>Ratio</param_type>
            <param_value>1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.952</ci_lower_limit>
            <ci_upper_limit>1.050</ci_upper_limit>
            <estimate_desc>The estimated value represents the ratio of geometric least squares means (albiglutide 50 mg) to placebo at 5 hr 30 min.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Secretion Rate (Measured by Mathematical Analysis of C-peptide Concentrations) During the Glucose Clamp Period</title>
        <description>The insulin secretion rate (ISR) was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters. ISR was measured at 1 hr, 1 hr 15 min, 1 hr 45 min, 2 hr, 2 hr 45 min, 3 hr, 3 hr 30 min, 3 hr 45 min, 4 hr 15 min, and 4 hr 30 min. Repeated-measures analysis of variance was performed on insulin secretion rate using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion Rate (Measured by Mathematical Analysis of C-peptide Concentrations) During the Glucose Clamp Period</title>
          <description>The insulin secretion rate (ISR) was estimated by the deconvolution of peripheral C-peptide concentrations using a 2-compartment model that utilizes population C-peptide kinetic parameters. ISR was measured at 1 hr, 1 hr 15 min, 1 hr 45 min, 2 hr, 2 hr 45 min, 3 hr, 3 hr 30 min, 3 hr 45 min, 4 hr 15 min, and 4 hr 30 min. Repeated-measures analysis of variance was performed on insulin secretion rate using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect.</description>
          <population>Pharmacodynamic Population</population>
          <units>Milliunits per hour (mU/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22992" spread="0.175853"/>
                    <measurement group_id="O2" value="0.15487" spread="0.111490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32088" spread="0.262743"/>
                    <measurement group_id="O2" value="0.22083" spread="0.143504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02309" spread="0.155010"/>
                    <measurement group_id="O2" value="-0.00873" spread="0.052095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14532" spread="0.152512"/>
                    <measurement group_id="O2" value="0.08063" spread="0.105769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01411" spread="0.038786"/>
                    <measurement group_id="O2" value="0.02484" spread="0.030589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03145" spread="0.042047"/>
                    <measurement group_id="O2" value="0.04148" spread="0.038344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02053" spread="0.047566"/>
                    <measurement group_id="O2" value="-0.00507" spread="0.033461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01197" spread="0.015914"/>
                    <measurement group_id="O2" value="0.01878" spread="0.014128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00892" spread="0.017889"/>
                    <measurement group_id="O2" value="0.01401" spread="0.009209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01868" spread="0.011193"/>
                    <measurement group_id="O2" value="0.02254" spread="0.003796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epinephrine Values During the Glucose Clamp Period</title>
        <description>Epinephrine levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Epinephrine Values During the Glucose Clamp Period</title>
          <description>Epinephrine levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
          <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
          <units>Nanograms per liter (ng/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr, n=19, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="1.38"/>
                    <measurement group_id="O2" value="59.4" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr, n=19, 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" spread="1.78"/>
                    <measurement group_id="O2" value="61.2" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min, n=18, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" spread="1.37"/>
                    <measurement group_id="O2" value="59.9" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="1.38"/>
                    <measurement group_id="O2" value="70.1" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr, n=20, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="1.44"/>
                    <measurement group_id="O2" value="81.5" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.9" spread="1.89"/>
                    <measurement group_id="O2" value="159.2" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr, n=19, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.1" spread="1.81"/>
                    <measurement group_id="O2" value="171.1" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min, n=19, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429.2" spread="1.73"/>
                    <measurement group_id="O2" value="372.3" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.3" spread="1.93"/>
                    <measurement group_id="O2" value="318.8" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="568.3" spread="1.93"/>
                    <measurement group_id="O2" value="519.5" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608.7" spread="1.80"/>
                    <measurement group_id="O2" value="505.6" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477.1" spread="1.97"/>
                    <measurement group_id="O2" value="395.4" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.6" spread="2.04"/>
                    <measurement group_id="O2" value="225.9" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.4" spread="2.14"/>
                    <measurement group_id="O2" value="154.4" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.5" spread="1.85"/>
                    <measurement group_id="O2" value="118.2" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Norepinephrine Values During the Glucose Clamp Period</title>
        <description>Norepinephrine levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Norepinephrine Values During the Glucose Clamp Period</title>
          <description>Norepinephrine levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
          <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
          <units>Nanograms per liter (ng/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.6" spread="1.45"/>
                    <measurement group_id="O2" value="357.0" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.1" spread="1.44"/>
                    <measurement group_id="O2" value="360.9" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min, n=19, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="382.3" spread="1.40"/>
                    <measurement group_id="O2" value="376.2" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.7" spread="1.48"/>
                    <measurement group_id="O2" value="424.6" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr, n=20, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346.3" spread="1.42"/>
                    <measurement group_id="O2" value="382.5" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425.5" spread="1.51"/>
                    <measurement group_id="O2" value="421.2" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425.0" spread="1.58"/>
                    <measurement group_id="O2" value="411.9" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="543.2" spread="1.59"/>
                    <measurement group_id="O2" value="519.2" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537.5" spread="1.57"/>
                    <measurement group_id="O2" value="447.5" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624.0" spread="1.55"/>
                    <measurement group_id="O2" value="618.0" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="649.5" spread="1.57"/>
                    <measurement group_id="O2" value="622.2" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="605.0" spread="1.63"/>
                    <measurement group_id="O2" value="605.8" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr , n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="508.4" spread="1.61"/>
                    <measurement group_id="O2" value="485.4" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="511.3" spread="1.56"/>
                    <measurement group_id="O2" value="464.4" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469.4" spread="1.50"/>
                    <measurement group_id="O2" value="444.7" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Hormone Values During the Glucose Clamp Period</title>
        <description>Growth hormone levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Hormone Values During the Glucose Clamp Period</title>
          <description>Growth hormone levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
          <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
          <units>Micrograms per liter (g/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="3.093"/>
                    <measurement group_id="O2" value="0.26" spread="2.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="2.170"/>
                    <measurement group_id="O2" value="0.23" spread="2.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="2.294"/>
                    <measurement group_id="O2" value="0.26" spread="2.722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="3.160"/>
                    <measurement group_id="O2" value="0.41" spread="3.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr, n=20, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="3.343"/>
                    <measurement group_id="O2" value="0.59" spread="4.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="2.910"/>
                    <measurement group_id="O2" value="2.25" spread="3.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="2.641"/>
                    <measurement group_id="O2" value="3.50" spread="1.971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="1.764"/>
                    <measurement group_id="O2" value="4.81" spread="1.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="1.868"/>
                    <measurement group_id="O2" value="4.61" spread="1.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="1.864"/>
                    <measurement group_id="O2" value="4.34" spread="1.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="1.722"/>
                    <measurement group_id="O2" value="4.16" spread="1.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="1.703"/>
                    <measurement group_id="O2" value="3.93" spread="1.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.778"/>
                    <measurement group_id="O2" value="2.99" spread="1.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="2.030"/>
                    <measurement group_id="O2" value="1.93" spread="1.945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="1.906"/>
                    <measurement group_id="O2" value="1.14" spread="2.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Values During the Glucose Clamp Period</title>
        <description>Insulin levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Values During the Glucose Clamp Period</title>
          <description>Insulin levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
          <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
          <units>Picomoles per liter (pmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.5" spread="1.60"/>
                    <measurement group_id="O2" value="102.4" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.5" spread="2.11"/>
                    <measurement group_id="O2" value="183.6" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.9" spread="2.14"/>
                    <measurement group_id="O2" value="270.9" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.6" spread="2.03"/>
                    <measurement group_id="O2" value="207.4" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr, n=20, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437.4" spread="2.01"/>
                    <measurement group_id="O2" value="357.3" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298.3" spread="2.05"/>
                    <measurement group_id="O2" value="191.9" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.2" spread="2.10"/>
                    <measurement group_id="O2" value="438.7" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="677.1" spread="2.34"/>
                    <measurement group_id="O2" value="488.0" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000.6" spread="2.66"/>
                    <measurement group_id="O2" value="861.2" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1738.7" spread="2.09"/>
                    <measurement group_id="O2" value="887.9" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1057.8" spread="3.60"/>
                    <measurement group_id="O2" value="758.1" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.0" spread="2.62"/>
                    <measurement group_id="O2" value="115.5" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.7" spread="2.39"/>
                    <measurement group_id="O2" value="75.6" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="2.05"/>
                    <measurement group_id="O2" value="69.6" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" spread="2.02"/>
                    <measurement group_id="O2" value="65.1" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cortisol Values During the Glucose Clamp Period</title>
        <description>Cortisol levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Cortisol Values During the Glucose Clamp Period</title>
          <description>Cortisol levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
          <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
          <units>Nanomoles per liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.9" spread="2.05"/>
                    <measurement group_id="O2" value="282.9" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.9" spread="2.05"/>
                    <measurement group_id="O2" value="250.5" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.4" spread="2.04"/>
                    <measurement group_id="O2" value="272.3" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.2" spread="2.04"/>
                    <measurement group_id="O2" value="230.2" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr, n=20, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.0" spread="2.04"/>
                    <measurement group_id="O2" value="230.7" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.9" spread="1.88"/>
                    <measurement group_id="O2" value="290.4" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.1" spread="1.50"/>
                    <measurement group_id="O2" value="344.0" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="597.0" spread="1.28"/>
                    <measurement group_id="O2" value="534.7" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667.7" spread="1.20"/>
                    <measurement group_id="O2" value="583.0" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="746.4" spread="1.21"/>
                    <measurement group_id="O2" value="674.0" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758.2" spread="1.20"/>
                    <measurement group_id="O2" value="705.2" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="780.0" spread="1.18"/>
                    <measurement group_id="O2" value="712.0" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="718.9" spread="1.32"/>
                    <measurement group_id="O2" value="673.3" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703.4" spread="1.20"/>
                    <measurement group_id="O2" value="626.8" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="646.4" spread="1.25"/>
                    <measurement group_id="O2" value="569.0" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-peptide Values During the Glucose Clamp Period</title>
        <description>C-peptide levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>C-peptide Values During the Glucose Clamp Period</title>
          <description>C-peptide levels were measured at all stages of glycemia during the glucose clamp period. Epinephrine levels were measured at each clamped glucose concentration: 9 millimoles per liter (mmol/L) (0 hour [hr], 1hr, 1 hr 15 minutes [min]), 5 mmol/L (1 hr 45 min, 2 hr), 4 mmol/L (2 hr 45 min, 3 hr), 3.3 mmol/L (3 hr 30 min, 3 hr 45 min), and 2.8 mmol/L (4 hr 15 min, 4 hr 30 min), and clamp released (4 hr 45 min, 5 hr, 5 hr 15 min, 5 hr 30 min). Repeated-measures analysis of variance was performed on log-transformed pharmacodynamic parameters using a model with treatment, time, and treatment-by-time as fixed effects, and participant as a random effect. Values below the lower limit of quantification were set to the quantification limit for summary.</description>
          <population>Pharmacodynamic Population. Different participants may have been analyzed at different time points (reflected by n=X, X in the category titles), so the overall number of participants analyzed reflects everyone in the Pharmacodynamic Population.</population>
          <units>Nanomoles per liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.095" spread="1.4141"/>
                    <measurement group_id="O2" value="0.836" spread="1.2694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.616" spread="1.9504"/>
                    <measurement group_id="O2" value="0.993" spread="1.8530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.630" spread="1.9941"/>
                    <measurement group_id="O2" value="1.053" spread="1.8949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.786" spread="2.2046"/>
                    <measurement group_id="O2" value="0.517" spread="1.8094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr, n=20, 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.723" spread="2.1648"/>
                    <measurement group_id="O2" value="0.484" spread="1.8073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.362" spread="2.2903"/>
                    <measurement group_id="O2" value="0.275" spread="1.8736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.309" spread="2.2762"/>
                    <measurement group_id="O2" value="0.255" spread="1.8769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" spread="1.7438"/>
                    <measurement group_id="O2" value="0.138" spread="1.3718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" spread="1.5595"/>
                    <measurement group_id="O2" value="0.128" spread="1.3047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" spread="1.1483"/>
                    <measurement group_id="O2" value="0.101" spread="1.0589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" spread="1.0000"/>
                    <measurement group_id="O2" value="0.100" spread="1.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hr 45 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.100" spread="1.0000"/>
                    <measurement group_id="O2" value="0.100" spread="1.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" spread="1.1483"/>
                    <measurement group_id="O2" value="0.103" spread="1.0821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 15 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="1.4512"/>
                    <measurement group_id="O2" value="0.120" spread="1.3662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hr 30 min, n=20, 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.141" spread="1.6701"/>
                    <measurement group_id="O2" value="0.138" spread="1.4534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recovery Time of Plasma Glucose Levels to &gt;=3.9 mmol/L (&gt;=70 mg/dL) From the Hypoglycemic Clamp Level of 2.8 Nmol/L (50.4 mg/dL)</title>
        <description>The effect of albiglutide and placebo on the recovery time of plasma glucose levels to &gt;=3.9 mmol/L (7&gt;=0 mg/dL) from the hypoglycemic clamp level of 2.8 nmol/L (50.4 mg/dL) was calculated as the time in minutes between switching off of the insulin infusion and reaching the level of &gt;=3.9 mmol/L (&gt;=70 mg/dL). Censored values were censored at 70 minutes. The median and 95% confidence interval data are obtained from Kaplan-Meier estimates.</description>
        <time_frame>Day 4</time_frame>
        <population>Pharmacodynamic Population</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Recovery Time of Plasma Glucose Levels to &gt;=3.9 mmol/L (&gt;=70 mg/dL) From the Hypoglycemic Clamp Level of 2.8 Nmol/L (50.4 mg/dL)</title>
          <description>The effect of albiglutide and placebo on the recovery time of plasma glucose levels to &gt;=3.9 mmol/L (7&gt;=0 mg/dL) from the hypoglycemic clamp level of 2.8 nmol/L (50.4 mg/dL) was calculated as the time in minutes between switching off of the insulin infusion and reaching the level of &gt;=3.9 mmol/L (&gt;=70 mg/dL). Censored values were censored at 70 minutes. The median and 95% confidence interval data are obtained from Kaplan-Meier estimates.</description>
          <population>Pharmacodynamic Population</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" lower_limit="30.00" upper_limit="45.00"/>
                    <measurement group_id="O2" value="30.00" lower_limit="25.00" upper_limit="40.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Albiglutide Concentration on the Day of the Clamp Procedure</title>
        <description>Plasma samples were taken from participants at two time points on Day 4 (at 0 hours and 4 hours and 45 minutes post-dose) of Week 1 of the study for albiglutide study drug level analyses. The average concentration for each participant was calculated as the mean of the concentrations at 0 hours and 4 hours 45 minutes. The clamp procedure is a glucose-controlled insulin infusion system. Variable infusions of glucose are administered to achieve various glucose target levels. It is a way of quantifying insulin secretion and resistance.</description>
        <time_frame>Day 4</time_frame>
        <population>Albiglutide Pharmacokinetic Population: all participants who had at least one sample to compute albiglutide exposure</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Albiglutide Concentration on the Day of the Clamp Procedure</title>
          <description>Plasma samples were taken from participants at two time points on Day 4 (at 0 hours and 4 hours and 45 minutes post-dose) of Week 1 of the study for albiglutide study drug level analyses. The average concentration for each participant was calculated as the mean of the concentrations at 0 hours and 4 hours 45 minutes. The clamp procedure is a glucose-controlled insulin infusion system. Variable infusions of glucose are administered to achieve various glucose target levels. It is a way of quantifying insulin secretion and resistance.</description>
          <population>Albiglutide Pharmacokinetic Population: all participants who had at least one sample to compute albiglutide exposure</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, Day 4, 0 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2110.5" spread="905.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Day 4, 4 hours 45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1968.7" spread="754.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2039.63" spread="826.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE) and Treatment-emergent Non-serious Adverse Event (AE) During the Clamp Period</title>
        <description>Treatment-emergent AEs are defined as those with an onset on or after study drug administration. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.</description>
        <time_frame>From the time the participant consented to participate in the study through the end of the study, or the final follow-up visit for participants who discontinued active participation in the study (up to 8 study weeks)</time_frame>
        <population>Safety Population: all participants who received one dose of albiglutide or placebo. The Safety Population was analyzed according to treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Albiglutide 50 mg</title>
            <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Treatment-emergent Serious Adverse Event (SAE) and Treatment-emergent Non-serious Adverse Event (AE) During the Clamp Period</title>
          <description>Treatment-emergent AEs are defined as those with an onset on or after study drug administration. An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect.</description>
          <population>Safety Population: all participants who received one dose of albiglutide or placebo. The Safety Population was analyzed according to treatment received.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-emergent SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and non-serious AEs were collected from the time the participant consented to participate in the study through the end of the study, or the final follow-up visit for participants who discontinued active participation in the study (up to 8 weeks).</time_frame>
      <desc>On-therapy SAEs and non-serious AEs (onset on or after the first day of study medication) were collected in members of the Safety Population, comprised of all randomly assigned study participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Albiglutide 50 mg</title>
          <description>Participants received a single dose of albiglutide (50 milligrams [mg]) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 millimoles per liter (mmol/L) (162, 90, 72, 59, and 50.4 milligrams per deciliter [mg/dL], respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received a single dose of matching placebo (50 mg) subcutaneously 3 days before employing a stepped hyper- and hypoglycemic clamp with glucose plateaus of 9.0, 5.0, 4.0, 3.3, and 2.8 mmol/L (162, 90, 72, 59, and 50.4 mg/dL, respectively). Glucose and insulin infusions were included as part of the clamp procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

